JP7390313B2 - Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 - Google Patents

Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 Download PDF

Info

Publication number
JP7390313B2
JP7390313B2 JP2020565928A JP2020565928A JP7390313B2 JP 7390313 B2 JP7390313 B2 JP 7390313B2 JP 2020565928 A JP2020565928 A JP 2020565928A JP 2020565928 A JP2020565928 A JP 2020565928A JP 7390313 B2 JP7390313 B2 JP 7390313B2
Authority
JP
Japan
Prior art keywords
cancer
mixture
mmol
tumor
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020565928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525270A (ja
JP2021525270A5 (cg-RX-API-DMAC7.html
Inventor
キヤン ナム,
ジェスン キム,
ドンシク パク,
イジン チョン,
ヨン-イン ヤン,
ファン キュ カン,
Original Assignee
キュリエント カンパニー, リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュリエント カンパニー, リミテッド filed Critical キュリエント カンパニー, リミテッド
Publication of JP2021525270A publication Critical patent/JP2021525270A/ja
Publication of JP2021525270A5 publication Critical patent/JP2021525270A5/ja
Priority to JP2023174642A priority Critical patent/JP2023168629A/ja
Application granted granted Critical
Publication of JP7390313B2 publication Critical patent/JP7390313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
JP2020565928A 2018-05-30 2019-05-31 Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体 Active JP7390313B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174642A JP2023168629A (ja) 2018-05-30 2023-10-06 Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862677902P 2018-05-30 2018-05-30
US62/677,902 2018-05-30
PCT/EP2019/064214 WO2019229251A1 (en) 2018-05-30 2019-05-31 Quinoline derivatives as inhibitors of axl/mer rtk and csf1r

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174642A Division JP2023168629A (ja) 2018-05-30 2023-10-06 Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体

Publications (3)

Publication Number Publication Date
JP2021525270A JP2021525270A (ja) 2021-09-24
JP2021525270A5 JP2021525270A5 (cg-RX-API-DMAC7.html) 2021-12-09
JP7390313B2 true JP7390313B2 (ja) 2023-12-01

Family

ID=66770463

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565928A Active JP7390313B2 (ja) 2018-05-30 2019-05-31 Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体
JP2023174642A Withdrawn JP2023168629A (ja) 2018-05-30 2023-10-06 Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174642A Withdrawn JP2023168629A (ja) 2018-05-30 2023-10-06 Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体

Country Status (13)

Country Link
US (1) US12162858B2 (cg-RX-API-DMAC7.html)
EP (1) EP3774776A1 (cg-RX-API-DMAC7.html)
JP (2) JP7390313B2 (cg-RX-API-DMAC7.html)
KR (1) KR102901476B1 (cg-RX-API-DMAC7.html)
CN (1) CN112313216B (cg-RX-API-DMAC7.html)
AU (1) AU2019276359B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020021370A2 (cg-RX-API-DMAC7.html)
CA (1) CA3097694A1 (cg-RX-API-DMAC7.html)
IL (1) IL278960B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020011636A (cg-RX-API-DMAC7.html)
PH (1) PH12020551806A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009971QA (cg-RX-API-DMAC7.html)
WO (1) WO2019229251A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
EP4499627A1 (en) * 2022-03-30 2025-02-05 Qurient Co., Ltd. New forms of n-(5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridin-2-yl)-1-propyl-4-(2,2,2-trifluoroethoxy)-1h-pyrazole-3-carboxamide hydrochloride
KR102921178B1 (ko) * 2023-11-16 2026-02-02 (주)신테카바이오 헤테로아릴 유도체 화합물 및 이의 용도
CN117637185B (zh) * 2024-01-25 2024-04-23 首都医科大学宣武医院 一种基于影像的颅咽管瘤治疗辅助决策方法、系统及设备
CN118593494B (zh) * 2024-08-08 2024-11-01 四川大学华西医院 Nampt抑制剂在制备预防和/或治疗色素沉着绒毛结节性滑膜炎的药物中的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2011045084A1 (en) 2009-10-16 2011-04-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
JP2013536813A (ja) 2010-08-28 2013-09-26 リード ディスカバリー センター ゲーエムベーハー Axl阻害剤としての薬学的に活性な化合物
JP2014506925A (ja) 2011-02-28 2014-03-20 カリトル サイエンシズ, エルエルシー 置換型キノリン化合物及び使用方法
WO2016104617A1 (ja) 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
JP2018511624A (ja) 2015-04-14 2018-04-26 キュリエント カンパニー, リミテッド Tam rtkインヒビターとしてのキノリン誘導体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
JP2021525755A (ja) * 2018-06-01 2021-09-27 ライジェル ファーマシューティカルズ, インコーポレイテッド チロシンキナーゼ阻害剤として有用なキノリン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017329A1 (en) 1995-11-07 1997-05-15 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2011045084A1 (en) 2009-10-16 2011-04-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
JP2013536813A (ja) 2010-08-28 2013-09-26 リード ディスカバリー センター ゲーエムベーハー Axl阻害剤としての薬学的に活性な化合物
JP2014506925A (ja) 2011-02-28 2014-03-20 カリトル サイエンシズ, エルエルシー 置換型キノリン化合物及び使用方法
WO2016104617A1 (ja) 2014-12-25 2016-06-30 小野薬品工業株式会社 キノリン誘導体
JP2018511624A (ja) 2015-04-14 2018-04-26 キュリエント カンパニー, リミテッド Tam rtkインヒビターとしてのキノリン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry,2015年11月10日,Vol.59(8),p.3593-3608
RN:2028271-26-1,DATABASE REGISTRY [Online], Retrieved from STN,2016年11月09日

Also Published As

Publication number Publication date
KR102901476B1 (ko) 2025-12-18
WO2019229251A1 (en) 2019-12-05
IL278960B2 (en) 2024-08-01
CN112313216A (zh) 2021-02-02
JP2023168629A (ja) 2023-11-24
US12162858B2 (en) 2024-12-10
US20210163448A1 (en) 2021-06-03
IL278960B1 (en) 2024-04-01
PH12020551806A1 (en) 2021-05-17
NZ768747A (en) 2025-06-27
AU2019276359B2 (en) 2024-10-03
AU2019276359A1 (en) 2020-10-29
CA3097694A1 (en) 2019-12-05
EP3774776A1 (en) 2021-02-17
KR20210020882A (ko) 2021-02-24
CN112313216B (zh) 2025-03-14
JP2021525270A (ja) 2021-09-24
SG11202009971QA (en) 2020-11-27
BR112020021370A2 (pt) 2021-01-19
IL278960A (en) 2021-01-31
MX2020011636A (es) 2020-12-07

Similar Documents

Publication Publication Date Title
JP2023168629A (ja) Axl/mer rtkおよびcsf1rの阻害剤としてのキノリン誘導体
TWI879811B (zh) 作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
KR102834408B1 (ko) Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체
EP3286177B1 (en) Quinoline derivatives as tam rtk inhibitors
JP2024020220A (ja) 免疫調節剤としての複素環式化合物
AU2011297889B2 (en) Pharmaceutically active compounds as Axl inhibitors
CN114650868A (zh) Helios的小分子降解剂及其使用方法
JP2021001196A (ja) Jakキナーゼ阻害剤としてのナフチリジン化合物
JP2021524842A (ja) Pd−l1免疫調節剤としてのテトラヒドロ−イミダゾ[4,5−c]ピリジン誘導体
AU2021254764A1 (en) Substituted pyridines for the treatment of inflammatory diseases
CN108601773B (zh) 作为pi3k/mtor抑制剂的稠合喹啉化合物
AU2018320416B2 (en) Pyridylpyridone compounds
RU2812631C2 (ru) Производные хинолина в качестве ингибиторов рецепторной тирозинкиназы axl/mer и csf1r
TW202535865A (zh) 泛素特異性加工蛋白酶1 (usp1) 化合物
CN121969630A (zh) 并内酰胺环类化合物及其用途
JP2025539086A (ja) 造血前駆細胞キナーゼ1のピリドン及びピリミジノン阻害剤
HK1243707B (en) Quinoline derivatives as tam rtk inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231120

R150 Certificate of patent or registration of utility model

Ref document number: 7390313

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150